Comparing mutational pathways to lopinavir resistance in HIV-1 subtypes B versus C

被引:3
|
作者
Posada-Cespedes, Susana [1 ,2 ]
Van Zyl, Gert [3 ,4 ]
Montazeri, Hesam [5 ]
Kuipers, Jack [1 ,2 ]
Rhee, Soo-Yon [6 ]
Kouyos, Roger [7 ,8 ,9 ]
Guenthard, Huldrych F. [7 ,8 ,9 ]
Beerenwinkel, Niko [1 ,2 ]
机构
[1] Swiss Fed Inst Technol, Dept Biosyst Sci & Engn, Basel, Switzerland
[2] SIB Swiss Inst Bioinformat, Basel, Switzerland
[3] Stellenbosch Univ, Fac Med & Hlth Sci, Div Med Virol, Cape Town, South Africa
[4] Natl Hlth Lab Serv, Cape Town, South Africa
[5] Univ Tehran, Inst Biochem & Biophys, Dept Bioinformat, Tehran, Iran
[6] Stanford Univ, Dept Med, Stanford, CA 94305 USA
[7] Univ Hosp Zurich, Div Infect Dis, Zurich, Switzerland
[8] Univ Hosp Zurich, Hosp Epidemiol, Zurich, Switzerland
[9] Univ Zurich, Inst Med Virol, Zurich, Switzerland
基金
瑞士国家科学基金会;
关键词
CANCER PROGRESSION MODELS; DRUG-RESISTANCE; REVERSE-TRANSCRIPTASE; ANTIRETROVIRAL THERAPY; EVOLUTIONARY PATHWAYS; PROTEASE; PATTERNS; DIVERSITY; EMERGENCE; SEQUENCES;
D O I
10.1371/journal.pcbi.1008363
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Author summary There is a disparity in the distribution of infections by HIV-1 subtype in the world. Subtype B is predominant in America, Australia and western and central Europe, and most therapeutic strategies are based on research and clinical studies on this subtype. However, non-B subtypes represent the majority of global HIV-1 infections; e.g., subtype C alone accounts for nearly half of all HIV-1 infections. We present a statistical framework enabling the comparison of patterns of accumulating mutations in different HIV-1 subtypes. Specifically, we compare the temporal ordering of lopinavir resistance mutations in HIV-1 subtypes B versus C. To this end, we combine the Hidden Conjunctive Bayesian Network (H-CBN) model with an approximate inference scheme enabling comparisons of larger networks. We show that the development of resistance to lopinavir differs significantly between subtypes B and C, such that findings based on subtype B sequences can not always be applied to sybtype C. The described methodology is suitable for comparing different subgroups in the context of other evolutionary processes. Although combination antiretroviral therapies seem to be effective at controlling HIV-1 infections regardless of the viral subtype, there is increasing evidence for subtype-specific drug resistance mutations. The order and rates at which resistance mutations accumulate in different subtypes also remain poorly understood. Most of this knowledge is derived from studies of subtype B genotypes, despite not being the most abundant subtype worldwide. Here, we present a methodology for the comparison of mutational networks in different HIV-1 subtypes, based on Hidden Conjunctive Bayesian Networks (H-CBN), a probabilistic model for inferring mutational networks from cross-sectional genotype data. We introduce a Monte Carlo sampling scheme for learning H-CBN models for a larger number of resistance mutations and develop a statistical test to assess differences in the inferred mutational networks between two groups. We apply this method to infer the temporal progression of mutations conferring resistance to the protease inhibitor lopinavir in a large cross-sectional cohort of HIV-1 subtype C genotypes from South Africa, as well as to a data set of subtype B genotypes obtained from the Stanford HIV Drug Resistance Database and the Swiss HIV Cohort Study. We find strong support for different initial mutational events in the protease, namely at residue 46 in subtype B and at residue 82 in subtype C. The inferred mutational networks for subtype B versus C are significantly different sharing only five constraints on the order of accumulating mutations with mutation at residue 54 as the parental event. The results also suggest that mutations can accumulate along various alternative paths within subtypes, as opposed to a unique total temporal ordering. Beyond HIV drug resistance, the statistical methodology is applicable more generally for the comparison of inferred mutational networks between any two groups.
引用
收藏
页数:25
相关论文
共 50 条
  • [1] Differential Drug Resistance Acquisition in HIV-1 of Subtypes B and C
    Soares, Esmeralda A. J. M.
    Santos, Andre F. A.
    Sousa, Thatiana M.
    Sprinz, Eduardo
    Martinez, Ana M. B.
    Silveira, Jussara
    Tanuri, Amilcar
    Soares, Marcelo A.
    PLOS ONE, 2007, 2 (08):
  • [2] Lopinavir/Ritonavir Resistance in Patients Infected With HIV-1: Two Divergent Resistance Pathways?
    Champenois, Karen
    Baras, Agathe
    Choisy, Philippe
    Ajana, Faiza
    Melliez, Hughes
    Bocket, Laurence
    Yazdanpanah, Yazdan
    JOURNAL OF MEDICAL VIROLOGY, 2011, 83 (10) : 1677 - 1681
  • [3] Interpreting resistance to lopinavir/ritonavir in HIV-1 subtype C patients
    Grossman, Z
    Torten, D
    Shahar, E
    Levy, I
    Risenberg, K
    Chowers, M
    Istomin, V
    Averbuch, D
    Burke, M
    Ram, D
    Maayan, S
    Lorber, M
    Schapiro, JM
    ANTIVIRAL THERAPY, 2003, 8 (03) : U101 - U101
  • [4] HIV-1 Protease Codon 36 Polymorphisms and Differential Development of Resistance to Nelfinavir, Lopinavir, and Atazanavir in Different HIV-1 Subtypes
    Lisovsky, Irene
    Schader, Susan M.
    Martinez-Cajas, Jorge-Luis
    Oliveira, Maureen
    Moisi, Daniela
    Wainberg, Mark A.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2010, 54 (07) : 2878 - 2885
  • [5] Evolutionary Dynamics of Tat in HIV-1 Subtypes B and C
    Roy, Chandra Nath
    Khandaker, Irona
    Oshitani, Hitoshi
    PLOS ONE, 2015, 10 (06):
  • [6] Heterogeneity of Gag mutational pathways in primary HIV-1 subtype C infection
    Novitsky, V.
    Wang, R.
    Lagakos, S.
    Margolin, L.
    Baca, J.
    Kebaabetswe, L.
    Rossenkhan, R.
    Moyo, S.
    Woldegabriel, E.
    van Widenfelt, E.
    Makhema, J.
    Essex, M.
    RETROVIROLOGY, 2009, 6
  • [7] HIV-1 mutational pathways under multidrug therapy
    Lawyer, Glenn
    Altmann, Andre
    Thielen, Alexander
    Zazzi, Maurizio
    Sonnerborg, Anders
    Lengauer, Thomas
    AIDS RESEARCH AND THERAPY, 2011, 8
  • [8] HIV-1 mutational pathways under multidrug therapy
    Glenn Lawyer
    André Altmann
    Alexander Thielen
    Maurizio Zazzi
    Anders Sönnerborg
    Thomas Lengauer
    AIDS Research and Therapy, 8
  • [10] Differential In Vitro Kinetics of Drug Resistance Mutation Acquisition in HIV-1 RT of Subtypes B and C
    Cunha, Rodrigo D.
    Abreu, Celina M.
    Gonzalez, Luis M. F.
    Nijhuis, Monique
    de Jong, Dorien
    Aguiar, Renato S.
    Afonso, Adriana O.
    Brindeiro, Rodrigo M.
    Tanuri, Amilcar
    PLOS ONE, 2012, 7 (10):